** Shares of drug developer NeuroBo Pharmaceuticals rise 3.3% to $3.43 premarket
** Co says its obesity drug was found to be safe and well tolerated and did not result in any serious adverse effects in an early-stage study conducted with 45 obese, otherwise healthy individuals
** The main goal of the study was to assess the safety and tolerability of the drug by monitoring adverse events
** Five subjects receiving the treatment reported adverse events vs 3 subjects in the placebo group - NRBO says
** As of last close, stock down 10.2% YTD
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.